LBF20000PG02: Difference between revisions
No edit summary |
No edit summary |
||
| (8 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
|LipidBank=XPR1708 | |LipidBank=XPR1708 | ||
|LipidMaps=LMFA03010145 | |LipidMaps=LMFA03010145 | ||
|SysName=9,15- | |SysName=9,15-Dioxo-11alpha-hydroxy-prostan-1-oic acid | ||
|Common Name=&&13,14-dihydro- | |Common Name=&&13,14-dihydro-15-keto Prostaglandin E_1&& | ||
|Source=13,14-dihydro-15keto PGE1 is a metabolite of PGE1.[[Reference:Hamberg_M:Samuelsson_B:,J. Biol. Chem.,1971,246,6713|{{RelationTable/GetFirstAuthor|Reference:Hamberg_M:Samuelsson_B:,J. Biol. Chem.,1971,246,6713}}]][[Reference:Leonhardt_A:Krauss_M:Gieler_U:Schweer_H:Happle_R:Seyberth_HW:,Br. J. Dermatol.,1997,136,337|{{RelationTable/GetFirstAuthor|Reference:Leonhardt_A:Krauss_M:Gieler_U:Schweer_H:Happle_R:Seyberth_HW:,Br. J. Dermatol.,1997,136,337}}]] | |Source=13,14-dihydro-15keto PGE1 is a metabolite of PGE1.[[Reference:Hamberg_M:Samuelsson_B:,J. Biol. Chem.,1971,246,6713|{{RelationTable/GetFirstAuthor|Reference:Hamberg_M:Samuelsson_B:,J. Biol. Chem.,1971,246,6713}}]][[Reference:Leonhardt_A:Krauss_M:Gieler_U:Schweer_H:Happle_R:Seyberth_HW:,Br. J. Dermatol.,1997,136,337|{{RelationTable/GetFirstAuthor|Reference:Leonhardt_A:Krauss_M:Gieler_U:Schweer_H:Happle_R:Seyberth_HW:,Br. J. Dermatol.,1997,136,337}}]] | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=13,14-dihydro-15keto PGE1 is a week inhibitor of ADP-induced platelet aggregation in human PRP. | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Latest revision as of 04:08, 21 April 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1708 |
| LipidMaps | LMFA03010145 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20000PG02 |
| 13,14-dihydro-15-keto Prostaglandin E1 | |
|---|---|
| |
| Structural Information | |
| 9,15-Dioxo-11α-hydroxy-prostan-1-oic acid | |
| |
| Formula | C20H34O5 |
| Exact Mass | 354.240624198 |
| Average Mass | 354.48096000000004 |
| SMILES | C(CCC(=O)CC[C@H]([C@H]1CCCCCCC(O)=O)[C@@H](CC1=O)O)CC |
| Physicochemical Information | |
| 13,14-dihydro-15keto PGE1 is a metabolite of PGE1. Hamberg_M et al. Leonhardt_A et al. | |
| 13,14-dihydro-15keto PGE1 is a week inhibitor of ADP-induced platelet aggregation in human PRP. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
